文献速递其他结缔组织病血管炎

淋巴管生成因子与系统性硬化症相关肺动脉高压的关联

Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2021-05-28

该队列研究在两个系统性硬化症(SSc)队列中检测淋巴管生成因子血清水平,发现SSc患者VEGF-C较低、Ang-2较高,且VEGF-C和sVEGFR-3与PAH发生风险独立相关,提示VEGF-C可能作为SSc患者早期PAH检测的标志物。

要点

  • SSc患者血清VEGF-C水平低于健康对照,Ang-2水平高于健康对照。
  • 调整年龄和性别后,VEGF-C与PAH发生风险负相关(HR 0.53)。
  • sVEGFR-3与PAH发生风险正相关(HR 1.21),VEGF-C可能是早期PAH检测标志物。

核心结论

  • SSc相关PAH发生过程中淋巴管生成失调,VEGF-C可能是SSc患者早期PAH检测的有前景标志物。

研究设计与样本

  • 队列研究,使用多重组珠试验检测两个SSc队列(识别队列n=371,PAH富集验证队列n=149)及健康对照(分别为100和68例)的血清淋巴管生成因子水平。
  • PAH由右心导管检查(RHC)识别,定义依据2015年ESC/ERS肺动脉高压诊断和治疗指南。
  • 预测分析纳入两个队列中全部251例RHC确认的SSc-PAH病例,采用logistic回归和Cox回归分析。

主要发现

  • 识别队列中,SSc患者VEGF-C平均血清水平为2.1±0.5 ng/ml,低于健康对照的2.5±0.4 ng/ml(P<0.001)。
  • 识别队列中,SSc患者Ang-2平均血清水平为6.1±7.6 ng/ml,高于健康对照的2.8±1.8 ng/ml(P<0.001)。
  • 合并两个队列251例SSc-PAH的预测分析中,调整年龄和性别后,VEGF-C预测PAH发生(HR 0.53,95%CI 0.29-0.97,P=0.04)。
  • 同一多变量Cox回归中,sVEGFR-3预测PAH发生(HR 1.21,95%CI 1.01-1.45,P=0.042)。

关键数值与推荐

  • PAH定义依据2015年ESC/ERS肺动脉高压诊断和治疗指南。
  • VEGF-C与SSc-PAH的关联在PAH富集RHC验证队列中得到确认。

临床怎么用

  • 对于SSc患者,可考虑检测血清VEGF-C和sVEGFR-3水平以辅助评估PAH发生风险。
  • VEGF-C较低和sVEGFR-3较高可能提示PAH风险增加,需结合RHC等标准评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Pulmonary arterial hypertension (PAH) is a major complication in systemic sclerosis (SSc), a disease marked by vascular and lymphatic vessel abnormalities. This study was undertaken to assess the role of the lymphangiogenic factors vascular endothelial growth factor C (VEGF-C) and angiopoietin 2 (Ang-2) and the soluble forms of their respective cognate receptors, soluble VEGF receptor 3 (sVEGFR-3) and soluble TIE-2, in patients with SSc, and to evaluate their predictive ability as markers for PAH development in SSc. METHODS: In this cohort study, we used multiplex bead assays to assess serum levels of lymphangiogenic factors in 2 well-characterized SSc cohorts: an unselected identification cohort of SSc patients from Oslo University Hospital (n = 371), and a PAH-enriched validation cohort of SSc patients from Zurich University Hospital and Oslo University Hospital (n = 149). As controls for the identification and validation cohorts, we obtained serum samples from 100 healthy individuals and 68 healthy individuals, respectively. Patients in whom SSc-related PAH was identified by right-sided heart catheterization (RHC) in both cohorts were studied in prediction analyses. PAH was defined according to the European Society of Cardiology/European Respiratory Society 2015 guidelines for the diagnosis and treatment of PAH. Associations of serum levels of lymphangiogenic factors with the risk of PAH development were assessed in logistic regression and Cox regression analyses. Associations in Cox regression analyses were expressed as the hazard ratio (HR) with 95% confidence interval (95% CI). RESULTS: In the identification cohort, SSc patients had lower mean serum levels of VEGF-C and higher mean serum levels of Ang-2 compared to healthy controls (for VEGF-C, mean ± SD 2.1 ± 0.5 ng/ml in patients versus 2.5 ± 0.4 ng/ml in controls; for Ang-2, mean ± SD 6.1 ± 7.6 ng/ml in patients versus 2.8 ± 1.8 ng/ml in controls; each P < 0.001); these same trends were observed in SSc patients with PAH compared to those without PAH. The association of serum VEGF-C levels with SSc-PAH was confirmed in the PAH-enriched RHC validation cohort. For prediction analyses, we assembled all 251 cases of SSc-PAH identified by RHC from the identification and validation cohorts. In multivariable Cox regression analyses adjusted for age and sex, the mean serum levels of VEGF-C and sVEGFR-3 were predictive of PAH development in patients with SSc (for VEGF-C, HR 0.53 [95% CI 0.29-0.97], P = 0.04; for sVEGFR-3, HR 1.21 [95% CI 1.01-1.45], P = 0.042). CONCLUSION: These findings support the notion that lymphangiogenesis is deregulated during PAH development in SSc, and indicate that VEGF-C could be a promising marker for early PAH detection in patients with SSc.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Didriksen H, Molberg Ø, Fretheim H, et al. Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis. Arthritis Rheumatol. 2021. PMID: 33497027. doi:10.1002/art.41665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。